PTC Therapeutics Swings to Profit in Q2, Raises Guidance on Sephience Launch and Novartis Milestone
PTCT sits 75% above its 52-week low of $43.175.
Summary
PTC Therapeutics reported Q2 2026 revenue of $361 million, net income of $83.5 million, and raised full-year guidance. The quarter was driven by the Sephience launch and a $50 million milestone from Novartis. The company completed a $550 million convertible note offering, strengthening its balance sheet.
Key Events · Earnings and Guidance · PTCT
-
Q2 Revenue Surges to $361M
Total revenue reached $361 million, up 102% year-over-year, driven by $151 million in Sephience sales and a $50 million milestone from Novartis for initiating the Phase 3 votoplam trial.
-
Swings to Profitability
Net income came in at $83.5 million ($0.92 diluted EPS), compared to a net loss of $64.8 million in Q2 2025, reflecting operating leverage from product launches.
-
Full-Year Guidance Raised
Management raised full-year 2026 guidance, citing strong Sephience uptake and milestone revenue, signaling confidence in sustained growth.
-
Balance Sheet Strengthened
The company completed a $550 million 0% convertible notes offering due 2031; proceeds were used to repurchase $222 million of 2026 notes, extending maturity and reducing near-term debt. Cash and marketable securities totaled $2.23 billion at quarter-end.
Analysis · PTCT · Life Sciences
A strong second quarter saw PTC Therapeutics deliver total revenue of $361 million, fueled by the Sephience launch and a $50 million milestone from Novartis. The company swung to a net profit of $83.5 million and raised its full-year guidance. A $550 million convertible note offering further strengthened the balance sheet, extending the cash runway. Reflecting the product's commercial success, Sephience sales triggered a $30 million milestone payment to former Censa securityholders. These results mark a significant financial turnaround and validate the company's pipeline strategy.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 35.8% of the 1045 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PTCT was trading at $75.49 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.3B. The 52-week trading range was $43.18 to $90.87. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.